Search results
Mar 30, 2022 · To evaluate the efficacy of ivermectin for the prevention of progression of Covid-19 resulting in hospitalization among outpatients with SARS-CoV-2 infection, we conducted a randomized,...
Sep 14, 2021 · The current evidence does not support using ivermectin for treating or preventing COVID-19 outside of well-designed randomized clinical studies. The review has an Altmetric Attention Score of more than 7000 and is currently the top scoring Cochrane review of all time by this measure.
Mar 13, 2024 · New research led by the University of Oxford has concluded that the antiparasitic drug ivermectin does not provide clinically meaningful benefits for treating COVID-19 in a largely vaccinated population.
Aug 1, 2024 · We included RCTs evaluating effects of oral ivermectin on clinical, non-clinical and safety outcomes in non-hospitalized or ambulatory COVID-19 patients, at early stage of disease. Comparators may include standard of care (SOC), placebo, or active drug.
Today JAMA publishes a new trial of ivermectin treatment for mild to moderate COVID-19 that addresses the possibility that the existing literature may have missed the efficacy of ivermectin because the previously tested dose (approximately 400 μg/kg daily for 3 days) was insufficient. 5 At a higher treatment dose (600 μg/kg daily) and longer ...
Mar 14, 2022 · The study found that treatment with ivermectin during the early stages of COVID-19 in 490 patients did not reduce the risk of progression to severe disease — 21.6% of the patients in the...
Apr 19, 2021 · In March 2021, the World Health Organisation (WHO) reviewed the evidence and concluded that Ivermectin should only be offered as treatment for Covid-19 as part of controlled clinical trials. It said this was because of low quality evidence as to its efficacy. The EMA announced a similar position the same month.
